文献速递胃肠动力与功能性疾病

膳食纤维补充治疗肠易激综合征:随机对照试验的系统评价与荟萃分析

Fiber Supplementation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Gastroenterology · 2026-08-14

该系统评价与荟萃分析检索MEDLINE、Embase、Web of Science和Cochrane CENTRAL(至2026年4月9日),纳入30项RCT共1904例成人IBS患者。整体胃肠道症状积分无显著改善(SMD -0.25,95%CI -0.67–0.17,P=0.25),但β-半乳寡糖可改善症状。

要点

  • 纤维补充剂使IBS临床应答率从44%提高至52%,车前子获益最明确。
  • 整体胃肠道症状积分无显著改善,但β-半乳寡糖亚组显示症状改善。
  • 多数结局无法按IBS亚型进行亚组分析,未来RCT应报告各亚型结局。

核心结论

  • 纤维补充剂(尤其是车前子)可诱导IBS临床应答,但对整体胃肠道症状积分无显著影响。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Embase、Web of Science和Cochrane CENTRAL(建库至2026年4月9日),纳入30项RCT共1904例成人IBS患者。
  • 纳入标准为成人IBS患者,比较纤维补充剂与合适安慰剂对照;二分类临床应答数据以风险比和95%CI汇总;PROSPERO注册号CRD42024600758。

主要发现

  • 检索识别4008条记录,最终纳入30项RCT共1904例IBS患者;最常见纤维类型为麦麸(n=7)、车前子(n=6)、菊粉型果聚糖(n=5)和β-半乳寡糖(n=2),2项RCT使用纤维联合给药。
  • 车前子特异性获益(RR 1.53,95%CI 1.06–2.19)。
  • 9项RCT(n=497)报告整体胃肠道症状整合评分,无显著效应(SMD -0.25,95%CI -0.67–0.17,P=0.25,I2=78%),但β-半乳寡糖可改善症状。
  • 多数结局无法按IBS亚型进行亚组分析。

关键数值与推荐

  • 车前子临床应答:RR 1.53(95%CI 1.06–2.19)。
  • 整体胃肠道症状整合评分:SMD -0.25(95%CI -0.67–0.17),P=0.25。

临床怎么用

  • 可考虑使用纤维补充剂(特别是车前子)改善IBS患者的临床应答。
  • 对整体胃肠道症状的改善期望应有限,β-半乳寡糖可能对症状有益。
  • 因缺乏按IBS亚型分析的数据,临床决策需结合个体情况。

局限性

  • 多数结局无法按IBS亚型进行亚组分析。
  • 整体胃肠道症状分析异质性较高(I2=78%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fiber supplementation is widely used and recommended for irritable bowel syndrome (IBS), however, there is no recent evidence synthesis. We aimed to investigate the efficacy of fiber supplements in IBS through a systematic review and meta-analysis of randomized controlled trials (RCTs). METHODS: We searched MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (inception to April 9, 2026). Trials that recruited adults with IBS and investigated fiber supplements compared with a suitable placebo control were included. Dichotomous clinical response data were summarized with risk ratios and 95% CIs. The review was registered prospectively on the international systematic review registry PROSPERO (CRD42024600758). RESULTS: The search identified 4008 records and 30 RCTs including 1904 people with IBS were eligible. The most common fiber types were wheat bran (n = 7), psyllium (n = 6), inulin-type fructans (n = 5), and β-galacto-oligosaccharides (n = 2); 2 RCTs used fiber co-administration. Sixteen RCTs (n = 1293) reported the clinical response; 52% responded to fiber vs 44% to control (risk ratio, 1.21; 95% CI, 1.03 to 1.41; P = .02; I2 = 38%), with a benefit for psyllium specifically (risk ratio, 1.53; 95% CI, 1.06 to 2.19). Nine RCTs (n = 497) reported overall GI symptoms (integrative scores) and found no significant effect (standardized mean difference, -0.25; 95% CI, -0.67 to 0.17; P = .25; I2 = 78%) except for β-galacto-oligosaccharides, which improved symptoms. Subgroup analysis for IBS subtype was not possible for most outcomes. CONCLUSIONS: Fiber supplementation, and psyllium specifically, leads to clinical response in IBS. Future RCTs should report outcomes for individual IBS subtypes or only recruit specific IBS subtypes to better enable identification of distinct patterns of response.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Staudacher HM, Rucco V, Mancell S, et al. Fiber Supplementation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Gastroenterology. 2026. PMID: 42600900. doi:10.1053/j.gastro.2026.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。